Navigation Links
NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
Date:11/9/2009

;, and the other NAI on the market, Relenza®, is contraindicated for this population." said Dr. Moss.

ABOUT NEXBIO

NexBio, Inc. is a privately held clinical-stage biopharmaceutical company located in San Diego. NexBio's mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase®), is an investigational drug that consists of an inhaled recombinant fusion protein. It inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic). The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, under BAA Contract HHSN266200600015C and grant U01-AI070281. Viradin(TM), invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. TOSAP® is a technology invented and developed by NexBio and is used to formulate DAS181 for inhalation, as well as to make nano/microparticles from virtually any type of molecule. TOSAP® is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

'/>"/>
SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... ANNAPOLIS, Md., May 8 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced a date ... Company,s first quarter 2009 financial results will now be ... hosting a conference call to discuss its first quarter ...
... Biosolutions has announced that it will increase its C-Reactive ... Protein is a protein found in the blood that ... indicates an increased state of inflammation in the body. ... physical states including injury, fever and infection. Inflammation is ...
... host call and webcast today at 5:00 p.m. Eastern to ... , SAN DIEGO, May 7 Orexigen(R) Therapeutics, ... on the treatment of obesity, today announced unaudited financial results ... Months Ended March 31, 2009 , As of March ...
Cached Biology Technology:Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results 9
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... article in Environmental Microbiology reveals that indigenous microbiota ... degrade crude oil. Scientists from the Estación Experimental ... Granada investigated in situ crude oil degradation after ... After a spill, hydrocarbons are subjected to physicochemical ...
... cancer of the mouth and throat, surgery is ... speech and swallowing dysfunction and external scarring. Researchers ... Department of Otorhinolaryngology/Head and Neck Surgery, have completed ... date ?that demonstrate the effective use of the ...
... advising breastfeeding moms that alcoholic beverages can improve their ... report that even moderate doses of alcohol affect the ... "This information is important for women," comments lead author ... drinking alcohol just to improve the quality or quantity ...
Cached Biology News:A hope for oil spill bioremediation 2Two new retroviruses—transmitted from animals—identified 2Two new retroviruses—transmitted from animals—identified 3Alcohol consumption disrupts breastfeeding hormones 2Alcohol consumption disrupts breastfeeding hormones 3
... designed with a variety of motion options ... in one unit. Shake, rock, roll and ... allow for hybridization and blotting procedures requiring ... The upper chamber uses a roller action ...
... for paramagnetic bead precipitation from standard 96-well ... with no additional accessories. The stand has ... SBS 96-well microplate footprint. The use of ... and fast (as little as 30 seconds) ...
... magnetic particle based purification systems provide high ... any sample. They offer increased throughput and ... systems- KingFisher, KingFisher mL and KingFisher 96, ... l. Each system consists of an instrument, ...
... The SPD101B is a no-frills, basic ... institution. Although economically priced, this unit still ... with a digitial display of time and ... aqueous samples and accepts a wide variety ...
Biology Products: